Israeli biotech Rosetta Genomics has been granted a US patent for its ability to differentiate between four types of kidney cancer.
Israeli biotech Rosetta Genomics has been granted a US patent for its gene signature method of distinguishing four different types of kidney cancer. The molecular diagnostic test recognizes the profile of 29 microRNAs that are expressed in patients with renal cancer.
http://www.rosettagx.com/files/press_releases/2016/012516_ROSG_Kidney_Tumor_Classification_Patent_FINAL.pdf
By: Michael Ordman
Click here for all of this week’s Good News from Israel.